You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 287 No. 10, March 13, 2002 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Clinical Cardiology
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (336)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Review
 •Congestive Heart Failure/ Cardiomyopathy
 •Alert me on articles by topic

CLINICIAN'S CORNER
Hypertrophic Cardiomyopathy

A Systematic Review

Barry J. Maron, MD

JAMA. 2002;287:1308-1320.

Context  Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardiomyopathy (HCM), a genetic cardiac disease caused by a variety of mutations in genes encoding sarcomeric proteins and characterized by a broad and expanding clinical spectrum.

Objectives  To clarify and summarize the relevant clinical issues and to profile rapidly evolving concepts regarding HCM.

Data Sources  Systematic analysis of the relevant HCM literature, accessed through MEDLINE (1966-2000), bibliographies, and interactions with investigators.

Study Selection and Data Extraction  Diverse information was assimilated into a rigorous and objective contemporary description of HCM, affording greatest weight to prospective, controlled, and evidence-based studies.

Data Synthesis  Hypertrophic cardiomyopathy is a relatively common genetic cardiac disease (1:500 in the general population) that is heterogeneous with respect to disease-causing mutations, presentation, prognosis, and treatment strategies. Visibility attached to HCM relates largely to its recognition as the most common cause of sudden death in the young (including competitive athletes). Clinical diagnosis is by 2-dimensional echocardiographic identification of otherwise unexplained left ventricular wall thickening in the presence of a nondilated cavity. Overall, HCM confers an annual mortality rate of about 1% and in most patients is compatible with little or no disability and normal life expectancy. Subsets with higher mortality or morbidity are linked to the complications of sudden death, progressive heart failure, and atrial fibrillation with embolic stroke. Treatment strategies depend on appropriate patient selection, including drug treatment for exertional dyspnea ({beta}-blockers, verapamil, disopyramide) and the septal myotomy-myectomy operation, which is the standard of care for severe refractory symptoms associated with marked outflow obstruction; alcohol septal ablation and pacing are alternatives to surgery for selected patients. High-risk patients may be treated effectively for sudden death prevention with the implantable cardioverter-defibrillator.

Conclusions  Substantial understanding has evolved regarding the epidemiology and clinical course of HCM, as well as novel treatment strategies that may alter its natural history. An appreciation that HCM, although an important cause of death and disability at all ages, does not invariably convey ominous prognosis and is compatible with normal longevity should dictate a large measure of reassurance for many patients.


Author Affiliation: Minneapolis Heart Institute Foundation, Minneapolis, Minn.


RELATED ARTICLE

March 13, 2002
JAMA. 2002;287(10):1333-1334.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy
Maron et al.
Circulation 2008;118:1541-1549.
ABSTRACT | FULL TEXT  

Bringing the obstruction back into hypertrophic cardiomyopathy
Murphy
Heart 2008;94:1249-1250.
FULL TEXT  

Exercise-induced systolic dysfunction in patients with non-obstructive hypertrophic cardiomyopathy and mutations in the cardiac troponin genes
Sakata et al.
Heart 2008;94:1282-1287.
ABSTRACT | FULL TEXT  

B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy
Kaski et al.
Heart 2008;94:1307-1311.
ABSTRACT | FULL TEXT  

Acute effects of alcohol septal ablation on systolic and diastolic left ventricular function in patients with hypertrophic obstructive cardiomyopathy
Steendijk et al.
Heart 2008;94:1318-1322.
ABSTRACT | FULL TEXT  

Homozygous mutation of MYBPC3 associated with severe infantile hypertrophic cardiomyopathy at high frequency among the Amish
Zahka et al.
Heart 2008;94:1326-1330.
ABSTRACT | FULL TEXT  

Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future
Ommen et al.
Heart 2008;94:1276-1281.
FULL TEXT  

Preparticipation screening for cardiovascular abnormalities in young competitive athletes
Papadakis et al.
BMJ 2008;337:a1596-a1596.
FULL TEXT  

Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy
Maron et al.
Circ Heart Fail 2008;1:184-191.
ABSTRACT | FULL TEXT  

Left ventricular outflow tract obstruction in the presence of asymmetric septal hypertrophy and accessory mitral valve tissue treated with alcohol septal ablation
Kim et al.
Eur J Echocardiogr 2008;9:720-724.
ABSTRACT | FULL TEXT  

Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy
Olivotto et al.
J Am Coll Cardiol 2008;52:559-566.
ABSTRACT | FULL TEXT  

Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy
Sorajja et al.
Circulation 2008;118:131-139.
ABSTRACT | FULL TEXT  

The Risk in Exercise Training
Foster et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2008;2:279-284.
ABSTRACT  

Impact of Percutaneous Transluminal Septal Myocardial Ablation on Refractory Paroxysmal Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy
Hosokawa et al.
ANGIOLOGY 2008;59:329-334.
ABSTRACT  

Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy
Saumarez et al.
Eur Heart J 2008;29:1653-1661.
ABSTRACT | FULL TEXT  

Spatial Relationship Between Coronary Microvascular Dysfunction and Delayed Contrast Enhancement in Patients with Hypertrophic Cardiomyopathy
Sotgia et al.
JNM 2008;49:1090-1096.
ABSTRACT | FULL TEXT  

A novel mouse model of X-linked cardiac hypertrophy
Leatherbury et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H2701-H2711.
ABSTRACT | FULL TEXT  

The 2006 American Heart Association Classification of Cardiomyopathies Is the Gold Standard
Maron
Circ Heart Fail 2008;1:72-76.
FULL TEXT  

Oral Disopyramide for the Acute Treatment of Severe Outflow Obstruction in Hypertrophic Cardiomyopathy in the ICU Setting
Sirak and Sherrid
Chest 2008;133:1243-1246.
ABSTRACT | FULL TEXT  

Myocardial deformation abnormalities in paediatric hypertrophic cardiomyopathy: are all aetiologies identical?
Ganame et al.
Eur J Echocardiogr 2008;0:jen150v1-7.
ABSTRACT | FULL TEXT  

Disease-Modifying Mutations in Familial Hypertrophic Cardiomyopathy: Complexity From Simplicity
Hilfiker-Kleiner and Knoll
Circulation 2008;117:1775-1777.
FULL TEXT  

Severe Heart Failure and Early Mortality in a Double-Mutation Mouse Model of Familial Hypertrophic Cardiomyopathy
Tsoutsman et al.
Circulation 2008;117:1820-1831.
ABSTRACT | FULL TEXT  

Medical Conditions Affecting Sports Participation
Rice and and the Council on Sports Medicine and Fitness
Pediatrics 2008;121:841-848.
ABSTRACT | FULL TEXT  

Tissue Doppler imaging to predict clinical course of patients with hypertrophic cardiomyopathy
Bayrak et al.
Eur J Echocardiogr 2008;9:278-283.
ABSTRACT | FULL TEXT  

Lys184 deletion in troponin I impairs relaxation kinetics and induces hypercontractility in murine cardiac myofibrils
Iorga et al.
Cardiovasc Res 2008;77:676-686.
ABSTRACT | FULL TEXT  

Pathology of Cardiac Surgery
Padera and Schoen
Card Surg Adult 2008;3:111-178.
FULL TEXT  

Regional myocardial deformation in children with hypertrophic cardiomyopathy: morphological and clinical correlations
Ganame et al.
Eur Heart J 2007;28:2886-2894.
ABSTRACT | FULL TEXT  

Myosin regulatory light chain E22K mutation results in decreased cardiac intracellular calcium and force transients
Szczesna-Cordary et al.
FASEB J. 2007;21:3974-3985.
ABSTRACT | FULL TEXT  

Electrocardiograms Should Be Included in Preparticipation Screening of Athletes
Myerburg and Vetter
Circulation 2007;116:2616-2626.
FULL TEXT  

Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy
McLeod et al.
Eur Heart J 2007;28:2583-2588.
ABSTRACT | FULL TEXT  

Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy
Daw et al.
Hum Mol Genet 2007;16:2463-2471.
ABSTRACT | FULL TEXT  

Gray zone problem in athletes
Kasikcioglu
Eur Heart J 2007;28:2415-2416.
FULL TEXT  

Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy
Maron et al.
JAMA 2007;298:405-412.
ABSTRACT | FULL TEXT  

Hypertrophic Cardiomyopathy, Sudden Death, and Implantable Cardiac Defibrillators: How Low the Bar?
Nishimura and Ommen
JAMA 2007;298:452-454.
FULL TEXT  

Surgical Myectomy Remains the Primary Treatment Option for Severely Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
Maron
Circulation 2007;116:196-206.
FULL TEXT  

Myocarditis in hypertrophic cardiomyopathy
Maron and Basso
Eur Heart J 2007;28:1663-1664.
FULL TEXT  

Polony Multiplex Analysis of Gene Expression (PMAGE) in Mouse Hypertrophic Cardiomyopathy
Kim et al.
Science 2007;316:1481-1484.
ABSTRACT | FULL TEXT  

Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy
Melacini et al.
Heart 2007;93:708-710.
ABSTRACT | FULL TEXT  

Effects of Resistance Training on Ventricular Function and Hypertrophy in a Rat Model
Barauna et al.
Clin Med Res 2007;5:114-120.
ABSTRACT | FULL TEXT  

Recommendations and Considerations Related to Preparticipation Screening for Cardiovascular Abnormalities in Competitive Athletes: 2007 Update: A Scientific Statement From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation
Maron et al.
Circulation 2007;115:1643-1655.
FULL TEXT  

Comparison of Surgical Septal Myectomy and Alcohol Septal Ablation With Cardiac Magnetic Resonance Imaging in Patients With Hypertrophic Obstructive Cardiomyopathy
Valeti et al.
J Am Coll Cardiol 2007;49:350-357.
ABSTRACT | FULL TEXT  

Structural Abnormalities of the Inferoseptal Left Ventricular Wall Detected by Cardiac Magnetic Resonance Imaging in Carriers of Hypertrophic Cardiomyopathy Mutations
Germans et al.
J Am Coll Cardiol 2006;48:2518-2523.
ABSTRACT | FULL TEXT  

Cardiac aldosterone in subjects with hypertrophic cardiomyopathy
Wenxia Chai et al.
Journal of Renin-Angiotensin-Aldosterone System 2006;7:225-230.
ABSTRACT  

Hypertrophic Cardiomyopathy: The Search for Obstruction
Nishimura and Ommen
Circulation 2006;114:2200-2202.
FULL TEXT  

Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction
Maron et al.
Circulation 2006;114:2232-2239.
ABSTRACT | FULL TEXT  

Commentary: the value of the ECG in the preparticipation sports physical examination: the Italian experience.
Vitiello
Pediatr. Rev. 2006;27:e75-e76.
FULL TEXT  

The Genetic Bases of Cardiomyopathies
Richard et al.
J Am Coll Cardiol 2006;48:A79-A89.
ABSTRACT | FULL TEXT  

The Heart of Trained Athletes: Cardiac Remodeling and the Risks of Sports, Including Sudden Death
Maron and Pelliccia
Circulation 2006;114:1633-1644.
FULL TEXT  

Alterations of Tension-dependent ATP Utilization in a Transgenic Rat Model of Hypertrophic Cardiomyopathy
Frey et al.
J. Biol. Chem. 2006;281:29575-29582.
ABSTRACT | FULL TEXT  

Trends in Sudden Cardiovascular Death in Young Competitive Athletes After Implementation of a Preparticipation Screening Program
Corrado et al.
JAMA 2006;296:1593-1601.
ABSTRACT | FULL TEXT  

Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene
Lekanne Deprez et al.
J. Med. Genet. 2006;43:829-832.
ABSTRACT | FULL TEXT  

Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function
Schmitt et al.
Proc. Natl. Acad. Sci. USA 2006;103:14525-14530.
ABSTRACT | FULL TEXT  

Overexpression of Bone Morphogenetic Protein 10 in Myocardium Disrupts Cardiac Postnatal Hypertrophic Growth
Chen et al.
J. Biol. Chem. 2006;281:27481-27491.
ABSTRACT | FULL TEXT  

Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes
Pelliccia et al.
Eur Heart J 2006;27:2196-2200.
ABSTRACT | FULL TEXT  

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Writing Committee Members et al.
Europace 2006;8:651-745.
FULL TEXT  

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Fuster et al.
J Am Coll Cardiol 2006;48:e149-e246.
FULL TEXT  

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Fuster et al.
Circulation 2006;114:e257-e354.
FULL TEXT  

Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy
Jassal et al.
Eur Heart J 2006;27:1805-1810.
ABSTRACT | FULL TEXT  

Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy
Harris et al.
Circulation 2006;114:216-225.
ABSTRACT | FULL TEXT  

Interpretation of electrocardiographic abnormalities in hypertrophic cardiomyopathy with cardiac magnetic resonance
Dumont et al.
Eur Heart J 2006;27:1725-1731.
ABSTRACT | FULL TEXT  

Single-Gene Mutations and Increased Left Ventricular Wall Thickness in the Community: The Framingham Heart Study
Morita et al.
Circulation 2006;113:2697-2705.
ABSTRACT | FULL TEXT  

Prognostic value of intra-left ventricular electromechanical asynchrony in patients with hypertrophic cardiomyopathy
D'Andrea et al.
Eur Heart J 2006;27:1311-1318.
ABSTRACT | FULL TEXT  

Management of hypertrophic cardiomyopathy.
Spirito and Autore
BMJ 2006;332:1251-1255.
FULL TEXT  

Novel Locus for an Inherited Cardiomyopathy Maps to Chromosome 7
Song et al.
Circulation 2006;113:2186-2192.
ABSTRACT | FULL TEXT  

Implantable Cardioverter- Defibrillator Therapy in Clinical Practice
Cesario and Dec
J Am Coll Cardiol 2006;47:1507-1517.
ABSTRACT | FULL TEXT  

Relevance of Coronary Microvascular Flow Impairment to Long-Term Remodeling and Systolic Dysfunction in Hypertrophic Cardiomyopathy
Olivotto et al.
J Am Coll Cardiol 2006;47:1043-1048.
ABSTRACT | FULL TEXT  

Exercise Can Prevent and Reverse the Severity of Hypertrophic Cardiomyopathy
Konhilas et al.
Circ. Res. 2006;98:540-548.
ABSTRACT | FULL TEXT  

Prognostic value of intra-left ventricular electromechanical asynchrony in patients with mild hypertrophic cardiomyopathy compared with power athletes * Commentary.
D'Andrea et al.
Br. J. Sports. Med. 2006;40:244-250.
ABSTRACT | FULL TEXT  

AHA/ACCF Scientific Statement on the Evaluation of Syncope: From the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation In Collaboration With the Heart Rhythm Society
Strickberger et al.
J Am Coll Cardiol 2006;47:473-484.
FULL TEXT  

AHA/ACCF Scientific Statement on the Evaluation of Syncope: From the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation: In Collaboration With the Heart Rhythm Society: Endorsed by the American Autonomic Society
Strickberger et al.
Circulation 2006;113:316-327.
FULL TEXT  

Hospital admission of patients referred to the Emergency Department for syncope: a single-hospital prospective study based on the application of the European Society of Cardiology Guidelines on syncope
Bartoletti et al.
Eur Heart J 2006;27:83-88.
ABSTRACT | FULL TEXT  

Medical and Legal Issues in the Cardiovascular Evaluation of Competitive Athletes
Paterick et al.
JAMA 2005;294:3011-3018.
ABSTRACT | FULL TEXT  

Tissue Doppler-Derived Indices Predict Exercise Capacity in Patients With Apical Hypertrophic Cardiomyopathy
Ha et al.
Chest 2005;128:3428-3433.
ABSTRACT | FULL TEXT  

Lifelong Left Ventricular Remodeling of Hypertrophic Cardiomyopathy Caused by a Founder Frameshift Deletion Mutation in the Cardiac Myosin-Binding Protein C Gene Among Japanese
Kubo et al.
J Am Coll Cardiol 2005;46:1737-1743.
ABSTRACT | FULL TEXT  

Are Longitudinal, Natural History Studies the Next Step in Genotype-Phenotype Translational Genomics in Hypertrophic Cardiomyopathy?
Ackerman et al.
J Am Coll Cardiol 2005;46:1744-1746.
FULL TEXT  

Danon Disease as an Underrecognized Cause of Hypertrophic Cardiomyopathy in Children
Yang et al.
Circulation 2005;112:1612-1617.
ABSTRACT | FULL TEXT  

Diagnostic accuracy of a 2D left ventricle hypertrophy score for familial hypertrophic cardiomyopathy
Forissier et al.
Eur Heart J 2005;26:1882-1886.
ABSTRACT | FULL TEXT  

Clinical Features and Outcomes of Childhood Hypertrophic Cardiomyopathy: Results From a National Population-Based Study
Nugent et al.
Circulation 2005;112:1332-1338.
ABSTRACT | FULL TEXT  

Prevalence and Clinical Significance of Left Atrial Remodeling in Competitive Athletes
Pelliccia et al.
J Am Coll Cardiol 2005;46:690-696.
ABSTRACT | FULL TEXT  

Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy
Rickers et al.
Circulation 2005;112:855-861.
ABSTRACT | FULL TEXT  

Prevention of Cardiac Hypertrophy by Atorvastatin in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy
Senthil et al.
Circ. Res. 2005;97:285-292.
ABSTRACT | FULL TEXT  

Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy
Ommen et al.
J Am Coll Cardiol 2005;46:470-476.
ABSTRACT | FULL TEXT  

Gender-Related Differences in the Clinical Presentation and Outcome of Hypertrophic Cardiomyopathy
Olivotto et al.
J Am Coll Cardiol 2005;46:480-487.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.